Focus: NKGEN Biotech is a public-stage biotechnology company headquartered in Santa Ana, CA, specializing in autologous and allogenic Natural Killer cell therapies for cancer, neuroinflammation, and other indications. The company is in early clinical development with a focused pipeline spanning gene and cell therapy modalities.
Profile data last refreshed 12h ago · AI intelligence enriched 2mo ago
Stable — net +1 jobs in 30d
1 added, 0 removed. Backfill posture.
NKGEN represents a speculative but innovative entry point for scientists and clinicians committed to next-generation cell therapy, but career stability and growth depend heavily on Phase 1–2 data readouts and ability to fund expansion.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for NKGEN Biotech
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from NKGEN Biotech's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
An investigational cell therapy for Alzheimer’s and Parkinson’s will be presented in Korea. - Stock Titan
An investigational cell therapy for Alzheimer’s and Parkinson’s will be presented in Korea. Stock Titan
Short Interest Alert: Most and least shorted sub-$2B healthcare stocks in Aug 2026 - Seeking Alpha
Short Interest Alert: Most and least shorted sub-$2B healthcare stocks in Aug 2026 Seeking Alpha
NKGen Biotech takes Alzheimer’s research global - Longevity.Technology
NKGen Biotech takes Alzheimer’s research global Longevity.Technology
NKGen Biotech to present Alzheimer’s drug trocu... - Pluang
NKGen Biotech to present Alzheimer’s drug trocu... Pluang
NKGen Biotech to present Alzheimer’s drug trocu... - Pluang
NKGen Biotech to present Alzheimer’s drug trocu... Pluang
NKGen Biotech to Present at the 2026 BIOCHINA Global Forum on Troculeucel’s Potential in Alzheimer’s Disease and Other Neurodegenerative Conditions - Yahoo Finance
NKGen Biotech to Present at the 2026 BIOCHINA Global Forum on Troculeucel’s Potential in Alzheimer’s Disease and Other Neurodegenerative Conditions Yahoo Finance
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo